Vericel (VCEL) Return on Capital Employed (2011 - 2026)
Vericel (VCEL) reported Return on Capital Employed of 3.59% for Q1 2026, up 431.0% on a YoY basis from 0.68% in Q1 2025, and up 36.91% sequentially from 2.62% in Q4 2025.
Vericel (VCEL) Return on Capital Employed (2011 - 2026) Analysis & Trends
Vericel (VCEL) has 16 years of Return on Capital Employed data on file, last reported at 3.59% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 431.0% year-over-year to 3.59%; the trailing twelve-month figure through Mar 2026 stood at 3.59% (up 431.0% YoY), and the FY2025 full-year result was 2.69%, up 137.0% from the prior year.
- Return on Capital Employed advanced to 3.59% in Q1 2026, from 2.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 3.59% in Q1 2026 to a low of 8.66% in Q3 2022.
- A 5-year average of 2.57% and a median of 1.18% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 1244 bps in 2022 and soared 630 bps in 2024, its largest moves.
- Tracing VCEL's Return on Capital Employed over 5 years: stood at 7.65% in 2022, then surged by 71 bps to 2.23% in 2023, then soared by 156 bps to 1.25% in 2024, then soared by 109 bps to 2.62% in 2025, then soared by 37 bps to 3.59% in 2026.
- Business Quant data shows VCEL's Return on Capital Employed at 3.59% in Q1 2026, 2.62% in Q4 2025, and 1.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 3.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.59% |
| Dec 31, 2025 | 2.62% |
| Sep 30, 2025 | 1.78% |
| Jun 30, 2025 | 0.31% |
| Mar 31, 2025 | -0.72% |
| Dec 31, 2024 | 1.25% |
| Sep 30, 2024 | -0.36% |
| Jun 30, 2024 | -1.18% |
| Mar 31, 2024 | -1.18% |
| Dec 31, 2023 | -2.23% |
| Sep 30, 2023 | -4.71% |
| Jun 30, 2023 | -5.88% |
| Mar 31, 2023 | -7.47% |
| Dec 31, 2022 | -7.65% |
| Sep 30, 2022 | -8.66% |
| Jun 30, 2022 | -7.90% |
| Mar 31, 2022 | -5.37% |
| Dec 31, 2021 | -3.78% |
| Sep 30, 2021 | 0.14% |
| Jun 30, 2021 | 4.55% |